Telmisartan is an orally effective, specific angiotensin II receptor (AT1 type) antagonist. Telmisartan binds to the AT1 subtype of angiotensin II receptors with high affinity and has no partial agonist effect at the AT1 receptor site. Telmisartan selectively binds to the AT1 receptor and the binding effect is long-lasting. Telmisartan has no affinity for other receptors (including AT2 and other AT receptors with fewer characteristics). Telmisartan can cause a decrease in blood aldosterone levels. Telmisartan does not inhibit human plasma renin or block ion channels. Telmisartan does not inhibit angiotensin converting enzyme (kinase II), so there will be no adverse reactions caused by enhanced bradykinin effects. Telmisartan can reduce systolic and diastolic blood pressure in hypertensive patients without affecting the pulse.

This product mainly acts on α receptors, directly stimulating α receptors. Its effect is weaker than that of norepinephrine but more persistent. Its cardiovascular effect is similar to that of norepinephrine. It can constrict blood vessels, continuously increase systolic and diastolic blood pressure, and enhance myocardial contractility. The cardiac output of normal people does not change much, but it can increase the cardiac output of patients with shock. The excitement of heart rate is not very significant, rarely causes arrhythmia, and has no central nervous system excitation effect. Because its pressor effect is reliable and lasts for a long time, it rarely causes reactions such as palpitations or decreased urine volume. When administered continuously, because this product indirectly replaces the transmitter in the adrenergic nerve vesicles, it can reduce the transmitter and weaken the intrinsic effect. Therefore, it cannot be stopped suddenly to avoid rebound hypotension.

This product is an immunomodulatory drug. It has the function of regulating and enhancing the cellular immune function of the human body. It can promote the maturation of T lymphocytes in the peripheral blood after mitogen activation, increase the secretion of various lymphokines (such as α, γ interferon, interleukin 2 and interleukin 3) after T cells are activated by various antigens or mitogens, and increase the level of lymphokine receptors on T cells. It also enhances the response of lymphocytes by activating T4 helper cells. In addition, this product may affect the chemotaxis of NK precursor cells, which become more cytotoxic after exposure to interferon. Therefore, this product has the function of regulating and enhancing the cellular immune function of the human body. This product is an immune bidirectional modulator. It has the function of inducing and promoting the differentiation, maturation and activation of T lymphocytes and their subsets, regulating T lymphocytes.

Coenzyme drugs are nucleotide derivatives that participate in the synthesis and metabolism of phospholipids and nucleic acids in the body. They are intermediate products and energy sources for brain phospholipid synthesis and nucleic acid metabolism.